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Abstract
Background: Spinal cord injury (SCI) induces secondary tissue damage that is associated with inflammation. We
have previously demonstrated that inflammation-related gene expression after SCI occurs in two waves - an initial
cluster that is acutely and transiently up-regulated within 24 hours, and a more delayed cluster that peaks between
72 hours and 7 days. Here we extend the microarray analysis of these gene clusters up to 6 months post-SCI.
Methods: Adult male rats were subjected to mild, moderate or severe spinal cord contusion injury at T9 using a
well-characterized weight-drop model. Tissue from the lesion epicenter was obtained 4 hours, 24 hours, 7 days, 28
days, 3 months or 6 months post-injury and processed for microarray analysis and protein expression.
Results: Anchor gene analysis using C1qB revealed a cluster of genes that showed elevated expression through 6
months post-injury, including galectin-3, p22
PHOX, gp91
PHOX, CD53 and progranulin. The expression of these genes
occurred primarily in microglia/macrophage cells and was confirmed at the protein level using both
immunohistochemistry and western blotting. As p22
PHOX and gp91
PHOX are components of the NADPH oxidase
enzyme, enzymatic activity and its role in SCI were assessed and NADPH oxidase activity was found to be
significantly up-regulated through 6 months post-injury. Further, treating rats with the nonspecific, irreversible
NADPH oxidase inhibitor diphenylene iodinium (DPI) reduced both lesion volume and expression of chronic gene
cluster proteins one month after trauma.
Conclusions: These data demonstrate that inflammation-related genes are chronically up-regulated after SCI and
may contribute to further tissue loss.
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Background
Spinal cord injury (SCI) is followed by delayed second-
ary damage that occurs for days, weeks and even
months following the initial insult [1,2]. Inflammation,
including the activation and migration of microglia and
macrophages, plays a significant role in this secondary
injury [3-9]. Microglia are the primary immune response
cells in the CNS [10] and can be activated by a number
of pro-inflammatory cytokines and chemokines or other
alterations in the CNS environment [11,12]. Microglia
respond quickly, within minutes, to environmental
changes such as increases in ATP concentration or
injury [13]. After SCI, microglia are the dominant
monocyte occupying the injury site through 3 days post-
injury, after which macrophages begin to invade the
lesion site [14]; immunocytochemically, the two cell
types are indistinguishable.
We have shown that genes associated with inflamma-
tion, including those expressed primarily by microglia/
macrophages, are strongly up-regulated immediately
after injury and remain up-regulated for at least 7 days
[15]. Further, Popovich et al. [16] has demonstrated that
areas of blood-spinal cord barrier permeability 14 to 28
days post-injury are associated with OX42 (microglia/
macrophage) labeling, suggesting extensive monocytic
activity at delayed time points post-injury.
Our earlier work investigated the delayed up-regula-
tion of expression of selected inflammation-related
genes up to 7 days after SCI [15]; these genes included
C1qB, CD53, galectin-3 and p22
PHOX,a m o n go t h e r s .
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SCI, they have all been shown to play important roles in
post-injury inflammation. For example, p22
PHOX is a
core component of the NADPH oxidase enzyme, which
plays a key role in the production of reactive oxygen
species (ROS). This enzyme is composed of 4 cytosolic
subunits (p40
PHOX, p47
PHOX, p67
PHOX and GTP-binding
protein p21-Rac1) and 2 membrane subunits (gp91
PHOX
and p22
PHOX) [17]. ROS and their derivatives can have
severe cytotoxic effects [18,19], including induction of
pro-inflammatory cytokine expression via MAPK and
NFB signaling [20]. Reduction of NADPH oxidase
activity can mitigate the microglial response and reduce
neuronal cell death [15,21-25]. Diphenylene iodonium
(DPI), a nonspecific, irreversible inhibitor of NADPH
oxidase, operates by modifying the heme component of
NADPH oxidase, disrupting the ability of the enzyme to
generate ROS [26,27]. DPI blocks NFB activation in
microglia, which reduces iNOS and cytokine production
[24]. Inhibition of NADPH oxidase with DPI also
impairs peroxynitrite production and suppresses micro-
glial-induced oligodendrocyte precursor cell death [28].
The goal of this work was to examine the chronic
expression of microglial-related genes, examining up to 6
months after SCI, and to begin to assess the relationship
and function of these proteins, particularly of NADPH oxi-
dase. The characterization of inflammatory gene expression
is important for understanding the role of inflammation,
including microglial and macrophage activation, in second-
ary injury for the development of SCI therapeutics.
Methods
Spinal Cord Injury
Contusion SCI was performed in adult male Sprague
Dawley rats as previously described [29]. Briefly, rats
(275 - 325 g) were anesthetized with sodium pentobarbi-
tal (67 mg/kg, I.P.) and mild, moderate or severe injury
was induced using a weight drop method, in which a 10
g weight was dropped from 17.5, 30, or 50 mm, respec-
tively, onto an impounder positioned on the exposed
spinal cord at vertebral level T-9. Sham injured animals
underwent the same experimental procedures, but
received a laminectomy only, without weight drop. All
experiments complied fully with the principles set forth
in the “G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r yA n i -
mals” prepared by the Committee on Care and Use of
Laboratory Animals of the Institute of Laboratory
Resources, National Research Council (DHEW pub. No.
(NIH) 85-23, 2985) and were approved by the George-
town University IACUC.
Expression Profiling
Animals were deeply anesthetized with sodium pento-
barbital (100 mg/kg, I.P.) and decapitated 4 hours, 24
hours, 7, 14 and 28 days and 3 or 6 months after injury.
A 1 cm section of the spinal cord centered at the lesion
epicenter, T-9, was dissected, and immediately frozen
on dry ice. Two naïve controls (rats that did not
undergo any surgical procedure) were also included in
the analysis.
Expression profiling was performed as described pre-
viously [15,30]. Briefly, 7 μg of total RNA was extracted
using TRIzol reagent (Invitrogen, Carlsbad, CA) and
used for complementary DNA (cDNA) and biotinylated
complementary RNA (cRNA) synthesis. RNA was then
hybridized to the Affymetrix rat U34A, B, and C arrays
according to the manufacturer’s protocol (Affymetrix,
Santa Clara, CA). Collectively these chips include
approximately 28,000 genes and ESTs. Samples were not
combined; each gene chip was dedicated to a single
spinal cord sample.
Microarray Quality control
We employed stringent quality control methods as pre-
viously published [31]. Each array fulfilled the following
quality control measures: cRNA fold changes between 5
to 10, scaling factor from 0.3-1.5, percentage of “pre-
sent” (P) calls from 40-55%, average signal intensity
levels between 900-1100, housekeeping genes and inter-
nal probe set controls showed > 80% present calls, con-
sistent values and 5’/3’ ratios were < 3.
Experimental normalization, data filtering and statisti-
cal analysis on gene expression profiles were generated
with the dChip probe-set algorithm and GeneSpring
software using a Welch ANOVA t-test p value <0.05
between sham and injured groups.
Pathway Analysis
The cluster of temporally correlated genes obtained
from the microarray was inputted into the GeneGo
MetaCore™ pathway analysis software (St. Joseph, MI).
Using the Direct Interactions, Shortest Path, and Tran-
scription Regulation algorithms, connectivity of the gene
list was obtained.
Western Blot
At 28 days and 6 months post-injury, 4 moderate-contu-
sion injured and 2 sham injured rats per time point
were anesthetized (100 mg/kg sodium pentobarbital, I.
P.) and decapitated. A 1 cm section of the spinal cord
(approximately 50 mg of tissue weight) centered at the
lesion epicenter, T-9, was dissected, and immediately
frozen on dry ice and western blot was performed as
described previously [15]. Briefly, tissue was homoge-
nized in RIPA Buffer and centrifuged to isolate protein.
Twenty-five μg of protein were run in SDS polyacryla-
mide gel electrophoresis and blotted onto a nitrocellu-
lose filter. The blot was then probed with antibodies
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Page 2 of 14against galectin-3 (1:1000; Abcam, Cambridge, MA),
progranulin (1:1000; R&D Systems, Minneapolis, MN),
gp91
PHOX (1:1000; BD Transduction Laboratories, San
Jose, CA) and p22
PHOX (1:1000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Immune complexes were detected
with appropriate secondary antibodies and chemilumi-
nescence reagents (Pierce, Rockford, IL). b-actin or
GAPDH were used as controls for gel loading and pro-
tein transfer. Scion Image Analysis (http://www.scion-
corp.com/) was used to assess pixel density of resultant
blots to compare between sham-injured and injured
spinal cord tissue.
Immunohistochemistry
At 28 days post-injury, 4 moderate-contusion injured
and 2 sham injured rats per time point were anesthe-
tized (100 mg/kg sodium pentobarbital, I.P.) and intra-
cardially perfused with 100 ml of 0.9% saline followed
by 300 ml of 10% buffered formalin. A 1 cm section of
spinal cord centered at the lesion epicenter, T-9, was
dissected, post-fixed in 10% buffered formalin overnight
and cryoprotected in 30% sucrose for 48 hours. Stan-
dard fluorescent immunocytochemistry on serial, 20 μm
thick coronal sections was performed as described pre-
viously [15]. Antibodies included NeuN (1:200; Milli-
p o r e ,B i l l e r i c a ,M A ) ,G F A P( 1 : 1 0 0 ;P r o m e g a ,M a d i s o n ,
WI), Iba-1 (1 μg/ml; Wako, Richmond, VA), C1q (1:100;
US Biologicals, Swampscott, MA), galectin-3 (6 μg/ml),
p22
PHOX (1:200), progranulin (1:200), and gp91
PHOX
(1:100). Appropriate secondary antibodies linked to
FITC or Cy3 fluorophores (Jackson Immunoresearch,
West Grove, PA) were incubated with tissue sections for
1 hour at room temperature. Slides were coverslipped
using mounting media containing DAPI to counterstain
for nuclei (Vector Labs, Bu r l i n g a m e ,C A ) .T oe n s u r e
accurate and specific staining, negative controls were
used in which the primary antibody was not applied to
sections from injured tissue, and only staining that
labeled cells that were double-labeled with expected cell
markers or had expected labeling patterns (i.e., classic
microglia morphology) was confirmed as positive label-
ing. Immunofluorescence was detected using confocal
microscopy or an AxioPlan Zeiss Microscopy system
(Carl Zeiss, Inc., Thornwood, NY).
Immunofluorescence was detected and quantified in
twelve 20 μm sections, selected with a random start and
consistent interslice distance, using confocal microscopy
as described previously [32]. In brief, the proportional
area of tissue occupied by immunohistochemically
stained cellular profiles within a defined target area (the
lesion site and surrounding tissue) was measured using
the Scion Image Analysis system using a method modi-
fied from Popovich and colleagues [33].
NADPH Oxidase Activity Assay
At 3 and 6 months post-injury, 4 moderate-contusion
injured and 2 sham injured rats per time point were
anesthetized (100 mg/kg sodium pentobarbital, I.P.) and
decapitated. A 1 cm section of the spinal cord (approxi-
mately 50 mg of tissue weight) centered at the lesion
epicenter, T-9, was dissected, and immediately frozen
on dry ice for NADPH oxidase activity assessment as
previously described [34]. Briefly, tissue was homoge-
nized in lysis buffer (50 mM Tris, 0.1 mM EDTA, 0.1
mM EGTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1
mM phenylmethylsulfonyl fluoride) and centrifuged at
16,000G for 15 minutes. The supernatant was then cen-
trifuged at 100,000G for 1 hr for cell fractionation. Forty
μg of protein from the membrane fraction was added to
lysis buffer and NADPH oxidase buffer, along with DHE
and NADPH and the plate was assessed at an emission
of 485 nm and absorption of 590 nm.
NADPH Oxidase Inhibition
For NADPH oxidase inhibition experiments, a polyethy-
lene catheter (P-100, 1.52 outside diameter) attached to
an Alzet mini-osmotic pump (Alzet, Cupertino, CA;
Model 2001) was inserted into the intrathecal space at
30 minutes post-injury and advanced toward the lesion
site, resting 1 - 2 mm below the lesion site, as described
previously [35]. The mini-osmotic pump was loaded
with either DPI (Sigma, St. Louis, MO; 100 μMi n1 %
DMSO in saline; n = 3) or vehicle (1% DMSO in saline;
n = 3) and administered 1 μl of drug (representing 0.1
pmoles/day) or vehicle per hour for 7 days (7 day infus-
ing pump).
MRI Analysis
At 28 days post-injury, rats underwent magnetic reso-
n a n c ei m a g i n g( M R I )u s i n ga7T e s l a2 0c mb o r eM R I
(Bruker Biospin Billerica, MA). Rats underwent a 2D T2
weighted imaging protocol, in which the field of view
was 90 × 90 mm. The TR = 3640 msec, TE = 121 msec,
MTX = 256 × 256. Hyperintense areas on the 9 slices of
each 90 × 90 mm MRI image was assessed using Image
J analysis software, as previously described [36].
Histological Analysis
The day after MRI imaging, spinal cord tissue was
excised and processed for cresyl violet staining and
lesion volume analysis as previously described {Byrnes,
2010 #3024}. Briefly, a 1 cm section of the spinal cord
centered at the lesion epicenter, T9, was dissected and
20 μm thick coronal sections were collected and stained
with cresyl violet. The Cavalieri method of stereology
was used to estimate lesion volume, using a random
start section followed by lesion volume measurement,
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every 400 μm.
Statistical Analysis
Quantitative data are presented as mean +/- standard
error of the mean. Lesion volume, western blot, and
immunohistochemical data were obtained by an investi-
gator blinded to treatment group. All data were analyzed
using Student’s t test or one-way ANOVA, where appro-
priate. All statistical tests were performed using the
GraphPad Prism Program, Version 3.02 for Windows
(GraphPad Software, San Diego, CA). A p value < 0.05
was considered statistically significant.
Results
Spinal cord injury induces long term changes in
expression of microglial-associated genes
Microarray analysis was performed 4 hours, 24 hours, 7
days, 14 days, 28 days, 3 months and 6 months after
mild, moderate and severe spinal cord contusion injury
at T9. Gene expression data was retrieved from Affyme-
trix high density oligonucleotide arrays of approximately
24,000 probe sets. Our previous paper [15] detailed the
expression of genes associated with microglial function
up to 7 days after SCI. Analysis of chronic expression
demonstrated additional expression profiles expanding
upon the previous data. In this study, anchor gene tem-
poral clustering methods identified two temporally dis-
tinct gene clusters with a correlation r
2 value of greater
than 0.98 (Figure 1, Table 1).
The ‘acute expression’ cluster, identified using the
anchor genes COX-2 and Osteopontin displayed a sig-
nificant increase in expression early after injury, fol-
l o w e db yar e d u c t i o ni ne x p r e s s i o nb yd a y7( F i g u r e1 ) .
There were 9 genes found to be temporally correlated
within this ‘acute expression’ cluster (Table 2).
Figure 1 Temporal profile patterns of the acute and delayed-
expression cluster. Time post-injury and group are represented on
the y-axis; specific genes are indicated on the x-axis. Gene
expression of injured and sham-injured samples are shown for the
lesion epicenter after mild, moderate and severe injuries. Note the
increase in expression at 4 h post-injury in the acute-expression
cluster, and the more delayed increase in intensity in the delayed-
expression cluster compared to that in the sham-injured group.
Cool colors represent decreased expression and warmer colors
indicate higher expression relative to naïve controls (yellow).
Table 1 Abbreviated gene clusters identified after SCI
Gene Name Description GenBank
Accession
Fold Change
4hr 24hr 72hr 7d 14d 28d 3mo 6mo
Group 1: Acute Expression
Ptgs2 (COX-
2)
Anchor Mediator of inflammatory functions, enzymatically
transforms arachidonic acid into prostaglandins
S67722 2.3* 1.3* 1.7 0.9 0.6 0.9 2.9 * 2.0 *
Osteopontin Pro-inflammatory cytokine NM_012881 1.6 5.0* 4.7* 4.6* 0.9 0 1.3 1.7 *
S100a8
(Calgranulin)
Calcium binding protein expressed by monocytes NM_053822 5.8* 5.5* 2.8* 0.9 0.1 1.3 0.9
Group 2: Delayed Expression
C1qB Anchor Component of the complement chain and binds antigen. x71127 0.97 2.2* 3.5* 7.1* 5.9 * 7.2 * 2.2 * 1.6 *
Galectin3 Galactose specific lectin that binds IgE and extracellular matrix
proteins.
JO2962 1.5* 2.4* 2.3* 10* 4.4 * 12.8* 4.0 * 4.0 *
P22/CYBa Core component of NADPH Oxidase within phagocytes. U18729 1.1 1.9* 2.8* 9.3* 7.8 * 4.4 * 1.7 * 1.4
OX44/CD53 Integral membrane protein that mediates signal transduction M57276 0.9 2.2* 3.5* 6.0* 3.8 * 5.3 * 3.2 * 2.1 *
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C1qB anchor gene, was not up-regulated until 24 to 48
hours after injury, but then remained up-regulated
throughout the study, up to 6 months post-injury (Table
1, Figure 1, 2). Expression of genes in this cluster
peaked between 7 and 28 days post-injury, and
remained elevated in comparison to sham-injured rats
through 6 months post-injury. This expression profile
was similar regardless of injury severity. Twenty-three
genes were found to be temporally correlated, with an r
2
value of greater than 0.99 in this cluster (Table 3).
Genes in the ‘delayed expression’ cluster include genes
previously identified [15], including p22
PHOX, galectin-3,
and AIF/MRF, as well as a selection of novel genes,
including progranulin and gp91
PHOX.T h e s eg e n e s
showed similar expression profiles, with expression
delayed until 7 days post-injury followed by prolonged
up-regulation for up to 6 months (Figure 2).
Pathway analysis shows ample connectivity between
clustered genes identified in the microarray
To determine connectivity amongst the delayed expres-
sion gene cluster, GeneGo’s MetaCore™ software was
used to perform a pathway analysis. ‘Direct Interaction’
algorithm analysis revealed that several genes were
Table 2 Acute Expression Cluster
Gene Name GenBank Accession
Ptgs2 (COX-2) Anchor S67722
Osteopontin/SPP1 NM_012881
S100a8 (Calgranulin) NM_053822
PGES Rc_AA944447_at
EST220254 rc_AI176662_s_at
EGR1 M18416_at
RGD1564664 rc_AA945679_s_at
LOC500300 rc_AA858817_at
RGD1560812 rc_AI230381_at
Gene name and GenBank Accession number of genes correlated at 0.98 or
above. EST or untranscribed sequences have not been included in this list.
Figure 2 Graphical representation of the expression of the delayed-expression cluster of genes. A subset of genes in the delayed-
expression cluster, including C1qB (C1q), CD53, p22
PHOX (Cyba), and galectin-3 (Lgals3) are graphed to demonstrate the fold expression change
over naïve from 4 hr to 6 months post-injury. Note the similar pattern of expression within the group as well as between injury severities
(Moderate, Mild, and Severe). Note also that expression of genes in the delayed-expression cluster remained up-regulated (above a 2 fold
increase) through 6 months post-injury.
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Page 5 of 14directly linked. FCgRIIa was suggested to directly acti-
vate galectin-3 (indicated by a dark green arrow in Fig-
ure 3). Moving up by one interaction showed that
DAP12 and Slp76 were also directly linked to FCgRIIa
and galectin-3, through interaction with Zap70, Syk and
SHP-1. In addition, CD53 and CD68 were linked
through interactions with c-Jun.
Pathways involving the delayed expression genes were
further explored using the ‘Shortest Path’ and ‘Transcrip-
tion Regulation’ algorithms. These pathways suggested
close interactions amongst the genes on the list, and simi-
lar transcriptional regulation (Figure 3). For example, the
ETS1 transcription factor was found to be linked to CD68,
p22
PHOX, CD53, and Slip76 (indicated by dark blue arrows
in Figure 3). SP1 was directly linked to CD68, BGLR,
p22
PHOX, CD53 and galectin-3 (indicated by light blue
arrows in Figure 3). Similar potential induction pathways
were also observed; IFNg, for example, was associated with
the expression of FCgRIIa, Slip76 and LAPTM5. Interest-
ingly, pro-inflammatory cytokines were identified as
potentially inducing the expression of several genes of the
delayed expression list; for example, TNFa and IL1b may
induce p22
PHOX and PTX3, which may induce C1qB
expression. Alternatively, anti-inflammatory cytokines
were associated with reduced expression of genes in the
delayed expression cluster. IL4, for example, reduced
FCgRIIa, CD68, and PTX3 expression. There were also
instances within the identified pathways where genes on
the list had functions that could induce expression of
other genes on the list. For example, DAP12 and FCgRIIa
w e r ef o u n dt ob ea s s o c i a t e dw i t hr e d u c e dA P 1a c t i v i t y ,
and reduction of AP1 could potentially increase galectin-3
expression.
Galectin-3 and Progranulin protein expression confirm
mRNA profiles
Galectin-3 and progranulin were selected to confirm that
mRNA up-regulation was paralleled by increases in pro-
tein expression using western blot and immunohisto-
chemistry at time points from 28 days through 6 months
post-injury. western blotting indicated that galectin-3
was significantly increased in injured tissue in compari-
son to sham-injured tissue at 28 days and 6 months post-
injury (Figure 4A, B). This was confirmed with immuno-
labeling, which demonstrated that galectin-3 was
expressed at high levels at 28d a y sp o s t - i n j u r yi nr o u n d /
ameboid shaped cells, indicative of activated and phago-
cytic microglia/macrophages( F i g u r e4 C-F ) .D o u b l e -
label immunohistochemistry was used to confirm expres-
sion of proteins of interest in microglia/macrophages and
other cell types. Galectin-3 was found to consistently
label a large subset of Iba-1 positive cells, indicating
microglial/macrophage expression (Figure 4F). No co-
labeling was found with NeuN or GFAP, indicating that
galectin-3 was not expressed in neurons or astrocytes,
respectively, at 28 days after SCI (data not shown). While
an assessment of the number of Iba-1/galectin-3 positive
cells was not done in this study, it was clear that the
majority of Iba-1 positive cells were also galectin-3 posi-
tive, and few galectin-3 positive cells were identified that
were not Iba-1 positive, suggesting that galectin-3 was
primarily expressed on microglia/macrophages.
Immunolabeling also confirmed the expression profile
observed in the microarray for progranulin (Figure 5A).
Progranulin was markedly increased in injured tissue at
28 days post-injury in contrast to sham-injured tissue
(Figure 5B). Double-immunolabeling demonstrated that
Iba-1 positive microglia/macrophages expressed progra-
nulin (Figure 5C). However, some neurons were also
positive for progranulin, as demonstrated by NeuN/pro-
granulin positive cells (Figure 5D). Progranulin was not
found in GFAP positive cells, however (data not shown).
NADPH oxidase component expression and activity
confirm mRNA expression profiles
The NADPH oxidase enzyme components p22
PHOX and
gp91
PHOX were both identified in the ‘delayed expression’
cluster. The protein products of these genes make up the
membrane-bound components of NADPH oxidase
Table 3 Delayed Expression Cluster
Gene Name GenBank
Accession
C1qB (Anchor) x71127
Fc receptor, IgG, low affinity III M32062_g_at
Glucuronidase, beta M13962mRNA#2_at
Similar to MS4A6B protein rc_AI012739_at
Galectin 3 JO2962
Capping protein (actin filament), gelsolin-like
(predicted)
rc_AA894004_at
Granulin X62322_g_at
P22/CYBa U18729
Tyro protein tyrosine kinase binding protein
(DAP12)
rc_AI102519_at
Lysosomal-associated protein transmembrane 5 rc_AA925353_at
CD68 antigen (predicted) rc_AI177761_at
OX44/CD53 M57276
Similar to carnosinase 1 rc_AI231438_at
Similar to MS4A6B protein rc_AI012739_at
Lymphocyte cytosolic protein 2 rc_AI060017_at
Cytochrome b-245, beta polypeptide (
gp91PHOX) rc_AA894029_at
V-maf musculoaponeurotic fibrosarcoma oncogene
family, protein B (avian)
rc_AI169152_at
Allograft inflammatory factor 1 U17919_s_at
Acid sphingomyelinase-like phosphodiesterase 3A rc_AI177804_at
Gene name and GenBank Accession number of genes correlated at 0.98 or
above. EST or untranscribed sequences have not been included in this list.
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cytic cells. To confirm that the increase in gene expres-
sion is accompanied by an increase in protein expression
and functional activity, western blotting, immunohisto-
chemistry and function assays were performed for
p22
PHOX and gp91
PHOX. Western blot analysis of
gp91
PHOX protein expression at 28 days post-injury indi-
cated an increase in expression in injured tissue com-
pared to sham tissue (Figure 6A). At 6 months post-
injury, western blotting demonstrated a significant
increase in p22
PHOX protein compared to sham, confirm-
ing the delayed expression suggested by the mRNA data
(Figure 6B). Immunohistochemistry at 28 days post-
injury demonstrated an increase in p22
PHOX immunola-
beling in contrast to sham-injured tissue (Figure 6C).
To confirm that the protein expression was accompa-
nied by an increase in functional activity, NADPH oxi-
dase activity was assessed at 3 and 6 months post-
injury. At both time points, NADPH oxidase activity
was significantly elevated above sham levels (Figure 7),
demonstrating that gene and protein expression is
accompanied by functional activity.
Inhibition of NADPH oxidase reduces lesion volume and
expression of other proteins in the ‘delayed expression
cluster’
Our data has demonstrated that NADPH oxidase
expression and activity is chronically up-regulated
after SCI. To determine if this enzyme plays a role in
chronic expression of microglial-related inflammatory
proteins after SCI, particularly those in the ‘delayed
expression cluster’, an inhibitor of NADPH oxidase,
DPI [37] was administered continuously for 7 days
starting 30 minutes after injury (n = 3/group). At 28
days post-injury, all rats underwent T2-weighted MRI
for assessment of post-injury lesion volume, which we
have previously shown to correlate with histological
measurements of lesion volume [38]. Vehicle-treated
Figure 3 Demonstration of pathway connections amongst genes of the delayed-expression group.T h e‘Transcriptional Regulation’
algorithm demonstrated a high degree of interconnection and pathway similarities amongst genes of the delayed-expression cluster (identified
with blue bubbles and highlighted in boxes). Genes are organized according to compartments, with extracellularly located proteins placed on
the left of the figure, and nuclear proteins on the right. Note the multiple connections between genes of the delayed-expression cluster and a
few transcription factors, including ETS1 and SP1, as well as common induction pathways, such as IFNg and TNFa. Green lines indicate positive
interactions; red lines indicate negative interactions. Connections of interest, for example between transcription factors and genes of interest and
direct interactions, have been highlighted.
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3 (Figure
8). A significant reduction in lesion volume was
found in rats that received DPI treatment (Figure 8;
0.05 +/- 0.01 cm
3). This reduction was confirmed
with histology. The day after MRI, tissue was
dissected and lesion volume measured in cresyl violet
stained sections. Based on histological measurements,
DPI-treated spinal cord had significantly (p < 0.05)
smaller lesion volume than vehicle-treated spinal cord
tissue (Figure 8).
Figure 4 Confirmation of galectin-3 expression at the protein level using western blotting and immunohistochemistry. Western blotting
was performed at 28 days and 6 months post-injury, and showed a significant increase in expression in moderately injured spinal cord over
sham-injured tissue. Representative western blots and graphical representations are shown in A, B. Immunohistochemistry was performed at 28
days post-injury. Sham-injured tissue demonstrated no positive immunostaining for galectin-3 (C, D). Galectin-3 positive cells (labeled with a
fluorescent red secondary antibody) were found throughout injured tissue at this time point, and labeled large, ameboid cells that are typical of
macrophages and activated microglia (E, F). DAPI (blue) was used as a counterstain for cells. Insets show magnified areas from the white matter.
Injured tissue double-labeled for microglia/macrophages (Iba-1) and galectin-3 (arrows) demonstrate correlation in expression in the merged
image (G). Size bar = 500 μM (C, E); 100 μM (D, F); 75 μm (G). Bars represent mean +/- SEM.
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Page 8 of 14Tissue was then assessed for multiple markers of
chronic inflammation 28 days after injury. Immunohisto-
chemistry was performed for the NADPH oxidase compo-
nent p22
PHOX and the chronically expressed inflammatory
proteins galectin-3 and progranulin. Immunolabeling for
p22
PHOX, progranulin and galectin-3 was significantly
reduced by DPI treatment (Figure 9). Western blotting
further confirmed the reduction of chronically expressed
progranulin after DPI treatment, with a significant reduc-
tion in expression at 28 days after injury in the treated
group in contrast to the vehicle group (Figure 9J).
Discussion
This work is a continuation and expansion of our pre-
vious findings demonstrating the existence of a delayed
expression cluster of inflammation-related genes [15].
Here we demonstrate that SCI results in a marked
chronic up-regulation of the expression of a cluster of
inflammation-related genes. Secondary injury, including
chronic demyelination, also lasts for weeks to months
after SCI [39]. A recent study by Naphade et al. [40]
demonstrated a secondary peak of inflammation as late
as 2 months post-injury. It is possible that this chronic
inflammatory response may contribute to the continua-
tion of damage in the injured cord.
Further, certain of these genes have been found to be
up-regulated in other CNS injury and neurodegenerative
models. For example, C1qB expression is increased in
areas of demyelination in amyotrophic lateral scleroris
(ALS) patients [41]. Both C1qB and galectin-3 are up-
Figure 5 mRNA and protein expression profile of progranulin after spinal cord injury. Expression of progranulin was identified in the
microarray and followed the expression profile of the delayed-expression cluster. Expression of progranulin peaked at 7 days post-injury and
remained up-regulated through the end of the study (A). Protein expression was confirmed using immunohistochemistry at 28 days post-injury.
Sham-injured tissue showed no progranulin positive cells at the lesion site (B). Injured tissue, however showed a large number of progranulin-
positive cells (B). Double-labeling with Iba-1 (C) and NeuN (D) showed correlation of expression in microglia and neurons. Size bar = 200 μm (B),
100 μm (C, D).
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Page 9 of 14regulated after traumatic brain injury [42]. Galectin-3
has also been shown to be increased after hypoxia/ische-
mia from 72 hours [43] to at least 2 months post-injury
[44]. Progranulin, which has recently been shown to
have delayed expression after SCI [40], has also been
shown to be increased in microglia in Alzheimer’s[ 4 5 ]
and ALS disease cases [46].
It is currently unclear if the protein products of the
delayed expression cluster play beneficial or detrimental
roles after SCI, as recent studies have sparked interest
in the pro-inflammatory M1 and anti-inflammatory M2
phenotypes of microglia and macrophages [47]. While
the M1/M2 status of cells expressing genes of interest
was not explored in this study, it is important to note
that many of the genes in the delayed expression cluster
can have both advantageous and deleterious effects after
injury. For example, progranulin is reportedly associated
with both pro- and anti-inflammatory responses,
depending upon the availability of the serine protease
elastase [45,48]. Elastase is produced by cells of myeloid
lineage, such as microglia; in areas with large amounts
of elastase, progranulin is cleaved into granulins. Granu-
lins, in turn, can be chemoattractants for macrophages
and other inflammatory cells and can induce cytokine
production [49,50]. Galectin-3 is also related to both
deleterious and regenerative responses after injury. For
example, it can directly induce the expression of cyto-
kines, such as IL6 and TNFa [51]. After nerve transec-
tion, galectin-3 knockout resulted in significant
increases in both the number of regrowing axons and
the rate at which function was recovered [52]. Further,
knockout of the gene in mice exposed to hypoxia-ische-
mia reduced white matter loss and markers of apoptosis
[43]. However, galectin-3 knockout can reduce phagocy-
tosis, which may impede debris clearance and regenera-
tion [53].
The amount of interaction amongst the genes of the
delayed expression cluster is also currently unknown.
Interactions have been noted in the literature, including
evidence of increased ROS production following C1q or
galectin-3 administration to cells [54-56]. Computational
pathways analysis revealed that, while there are few
direct interactions between genes of the delayed-expres-
sion group, these genes mayb ei n t i m a t e l yc o n n e c t e d
with similar up-stream and down-stream signaling path-
ways. Common transcription factors may partially
explain the similar patterns of up- and down-regulation
over time seen within a cluster. In this regard, a small
Figure 6 Confirmation of components of the NADPH oxidase enzyme. NADPH oxidase components gp91
PHOX (A) and p22
PHOX (B) were
confirmed using western blotting at 28 days and 6 months post-injury. Representative western blots and graphical representation are shown.
Bars represent mean +/- SEM. *p < 0.05. p22
PHOX expression was also confirmed with immunohistochemistry at 28 days post-injury in injured (C)
and sham-injured (D) tissue. No immunolabeling was observed in negative controls where primary antibody was excluded (E), and positive
labeling had typical ramified or ‘bushy’ appearance of microglia/macrophages. Size bar = 100 μM.
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Page 10 of 14group of transcription factors, notably ETS1 and SP1,
were associated with many of the genes within the
delayed-expression cluster. It is interesting to note that
ETS1 and SP1 activity have not been identified pre-
viously in SCI models, despite their integral roles in the
expression of several components of the inflammatory
pathway [57,58], such as NAPDH oxidase components
[59,60]. It is also possible that this chronic up-regulation
of gene expression is a result of stimulation due to a
positive feedback loop. For example, it has been shown
that transcription factors, such as AP1 and SP1, are sen-
sitive to ROS activation [61]. In fact, knockout of com-
ponents of the NAPDH oxidase enzyme inhibit AP1
transcriptional activity [62].
Supporting this theory was the finding that DPI
administration reduced the expression of progranulin,
galectin-3 and p22
PHOX. Moreover, T2-weighted MRI
and histology revealed significantly reduced lesion
volume in DPI-treated rats, suggesting that these inflam-
matory responses may be related to secondary injury
and expansion of the lesion site after SCI. Our previous
work has demonstrated that there is a significant corre-
lation between MRI-based lesion volume and histologi-
cal findings [36,38]. These data are in line with previous
findings, where administration of apocynin, an alterna-
tive NADPH oxidase inhibitor, after transient middle
cerebral artery occlusion reduced infarct volume [63].
Apocynin was also found to limit microglial and astro-
cytic activity in the hippocampus after ischemia, sug-
gesting reductions in overall inflammatory responses
[64]. It is important to note that DPI is a nonspecific
inhibitor of NADPH oxidase, and has been shown to
have actions on other flavin-containing enzymes. There-
fore, future work will explore the effects of more specific
NADPH oxidase inhibitors on SCI recovery, including
motor functional recovery and axonal preservation.
Figure 7 NADPH oxidase enzyme activity profile after spinal
cord injury. NADPH oxidase enzyme activity was also assessed to
confirm that gene and protein expression translated to enzymatic
activity. NADPH oxidase activity was measured in sham and injured
spinal cord tissue at 3 and 6 months post-injury. Bars represent
mean +/- SEM. *p < 0.05.
Figure 8 The effect of DPI on lesion volume after spinal cord
injury. Lesion volume in vehicle and DPI-treated injured spinal
cords was measured at 28 days post-injury using T2-weighted MRI
and histology. Representative MRI images of the lesion
(hyperintense region, arrow) are shown for vehicle (A) and DPI-
treated (B) spinal cords (outlined with dotted line). Representative
cresyl violet images are shown for vehicle (D) and DPI-treated (E)
spinal cords as well. Quantitation of MRI (C) and histology (F) based
measurements are shown. Bar size = 0.25 cm (A, B); 200 μm (D, E).
Bars represent mean +/- SEM. *p < 0.05. N = 3/group.
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Page 11 of 14In summary, these findings show that SCI in the rodent
is followed by a delayed up-regulation of pro-inflammatory
genes that may play a role in secondary injury. These
genes are related by similar up-stream regulators,
including both transcription factors and inducers. NADPH
oxidase, in particular, may play a significant role in propa-
gating chronic expression of these genes, and may serve as
a target for therapeutic intervention after SCI.
Figure 9 The effect of DPI on inflammatory markers after spinal cord injury. Inflammatory markers were compared in Vehicle (left image)
and DPI-treated (right image) spinal cord injured tissue at 28 days post-injury. DPI resulted in significant reductions in p22
PHOX (red, A, B),
progranulin (red, D, E) and galectin-3 (green, G, H) immunolabeling. DAPI-labeled nuclei are shown for contrast in G, H. Immunolabeling was
quantified and graphs are shown (C, F, I). Western blotting for progranulin was performed at 28 days post-injury, and revealed a significant
decrease in progranulin protein expression in the DPI treated group (J). Representative samples of the western blot are shown. Size bar = 500
μM. Bars represent mean +/- SEM; *p < 0.05.
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